Microbrachytherapy using holmium-166 acetylacetonate microspheres: A pilot study in a spontaneous cancer animal model

Abstract Purpose Holmium-166 acetylacetonate microspheres (166 Ho-AcAc-MS) are proposed as an intratumoral radioablation device. This article presents a pilot study in housecats with unresectable liver cancer. Feasibility and tolerability of intratumoral administrations of166 Ho-AcAc-MS was investig...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Brachytherapy 2013-03, Vol.12 (2), p.171-177
Hauptverfasser: Bult, Wouter, Vente, Maarten A.D, Vandermeulen, Eva, Gielen, Ingrid, Seevinck, Peter R, Saunders, Jimmy, van het Schip, Alfred D, Bakker, Chris J.G, Krijger, Gerard C, Peremans, Kathelijne, Nijsen, Johannes F.W
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 177
container_issue 2
container_start_page 171
container_title Brachytherapy
container_volume 12
creator Bult, Wouter
Vente, Maarten A.D
Vandermeulen, Eva
Gielen, Ingrid
Seevinck, Peter R
Saunders, Jimmy
van het Schip, Alfred D
Bakker, Chris J.G
Krijger, Gerard C
Peremans, Kathelijne
Nijsen, Johannes F.W
description Abstract Purpose Holmium-166 acetylacetonate microspheres (166 Ho-AcAc-MS) are proposed as an intratumoral radioablation device. This article presents a pilot study in housecats with unresectable liver cancer. Feasibility and tolerability of intratumoral administrations of166 Ho-AcAc-MS was investigated. Methods and Materials Three cats with unresectable liver tumors of different histotype were included. One cat had hepatocellular carcinoma (HCC), one had cholangiocarcinoma (CC), and one had a malignant epithelial liver tumor (MELT) of unspecified histotype.166 Ho-AcAc-MS were injected percutaneously under ultrasound guidance into the tumors. Followup consisted of physical examinations and hematologic and biochemical analyses. Results166 Ho-AcAc-MS were administered to three liver tumor-bearing cats. The treatment was well tolerated and the clinical condition, that is body weight, alertness, mobility, and coat condition of the animals improved markedly. Most biochemical and hematologic parameters normalized shortly after treatment. Life of all cats was extended and associated with a good quality of life. The HCC cat that received 33-Gy tumor-absorbed dose was euthanized 6 months after the first administration owing to disease progression. The MELT cat received 99-Gy tumor dose and was euthanized 3 months posttreatment owing to bacterial meningitis. The CC cat received 333 Gy and succumbed 4 months after the first treatment owing to the formation of a pulmonary embolism. Conclusions Percutaneous intratumoral injection of radioactive166 Ho-AcAc-MS is feasible in liver tumor-bearing cats. The findings of this pilot study indicate that166 Ho-AcAc-MS may constitute safe brachytherapeutic microspheres and warrant studies to confirm the clinical utility of this novel brachytherapy device.
doi_str_mv 10.1016/j.brachy.2012.08.001
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1315634949</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1538472112001924</els_id><sourcerecordid>1315634949</sourcerecordid><originalsourceid>FETCH-LOGICAL-c463t-8b4762ce8c42575d2c6453155e46ff887cae1ab11c8fbe58463f6c2510bc3a803</originalsourceid><addsrcrecordid>eNqFkbuO1jAQhSMEYi_wBgi5pEnwPQ4F0moFLNIiCqC2HGfC7x_HDnaClLfHURYKGlzYLs45M_NNVb0guCGYyNfnpk_GnraGYkIbrBqMyaPqkqiW1YTz7nH5C6Zq3lJyUV3lfC4C2TH2tLqgtCunFZfV-snZFI-k5QTJzBtaswvf0Sn6ya1TTaRExsKy-f2OwSyApt2U56KH_AbdoNn5uKC8rMOGXEAG5TmGxQSIa0bWBAsJmeAm49EUB_DPqiej8RmeP7zX1bf3777e3tX3nz98vL25ry2XbKlVz1tJLSjLqWjFQK3kghEhgMtxVKq1BojpCbFq7EGoYhqlpYLg3jKjMLuuXh25c4o_V8iLnly24P3RmiYlTDLe8a5I-SHdJ8sJRj2n0nDaNMF6B67P-sCkd-AaK114FtvLhwprP8Hw1_SHcBG8PQRQ5vzlIOlsHRQig0tgFz1E978K_wZY74Kzxv-ADfI5rikUhproXDz6y770feeEFndHOfsNUuCp6w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1315634949</pqid></control><display><type>article</type><title>Microbrachytherapy using holmium-166 acetylacetonate microspheres: A pilot study in a spontaneous cancer animal model</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Bult, Wouter ; Vente, Maarten A.D ; Vandermeulen, Eva ; Gielen, Ingrid ; Seevinck, Peter R ; Saunders, Jimmy ; van het Schip, Alfred D ; Bakker, Chris J.G ; Krijger, Gerard C ; Peremans, Kathelijne ; Nijsen, Johannes F.W</creator><creatorcontrib>Bult, Wouter ; Vente, Maarten A.D ; Vandermeulen, Eva ; Gielen, Ingrid ; Seevinck, Peter R ; Saunders, Jimmy ; van het Schip, Alfred D ; Bakker, Chris J.G ; Krijger, Gerard C ; Peremans, Kathelijne ; Nijsen, Johannes F.W</creatorcontrib><description>Abstract Purpose Holmium-166 acetylacetonate microspheres (166 Ho-AcAc-MS) are proposed as an intratumoral radioablation device. This article presents a pilot study in housecats with unresectable liver cancer. Feasibility and tolerability of intratumoral administrations of166 Ho-AcAc-MS was investigated. Methods and Materials Three cats with unresectable liver tumors of different histotype were included. One cat had hepatocellular carcinoma (HCC), one had cholangiocarcinoma (CC), and one had a malignant epithelial liver tumor (MELT) of unspecified histotype.166 Ho-AcAc-MS were injected percutaneously under ultrasound guidance into the tumors. Followup consisted of physical examinations and hematologic and biochemical analyses. Results166 Ho-AcAc-MS were administered to three liver tumor-bearing cats. The treatment was well tolerated and the clinical condition, that is body weight, alertness, mobility, and coat condition of the animals improved markedly. Most biochemical and hematologic parameters normalized shortly after treatment. Life of all cats was extended and associated with a good quality of life. The HCC cat that received 33-Gy tumor-absorbed dose was euthanized 6 months after the first administration owing to disease progression. The MELT cat received 99-Gy tumor dose and was euthanized 3 months posttreatment owing to bacterial meningitis. The CC cat received 333 Gy and succumbed 4 months after the first treatment owing to the formation of a pulmonary embolism. Conclusions Percutaneous intratumoral injection of radioactive166 Ho-AcAc-MS is feasible in liver tumor-bearing cats. The findings of this pilot study indicate that166 Ho-AcAc-MS may constitute safe brachytherapeutic microspheres and warrant studies to confirm the clinical utility of this novel brachytherapy device.</description><identifier>ISSN: 1538-4721</identifier><identifier>EISSN: 1873-1449</identifier><identifier>DOI: 10.1016/j.brachy.2012.08.001</identifier><identifier>PMID: 22999975</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Brachytherapy ; Brachytherapy - adverse effects ; Brachytherapy - instrumentation ; Brachytherapy - methods ; Cats ; Cell Line, Tumor ; Hematology, Oncology and Palliative Medicine ; Holmium - adverse effects ; Holmium - chemistry ; Holmium - therapeutic use ; Holmium-166 ; Hydroxybutyrates - chemistry ; Liver cancer ; Liver Neoplasms - radiotherapy ; Microsphere ; Microspheres ; Miniaturization ; Pentanones - chemistry ; Pilot Projects ; Radioablation ; Radioisotopes - adverse effects ; Radioisotopes - chemistry ; Radioisotopes - therapeutic use ; Radiology ; Treatment Outcome ; β-emitter</subject><ispartof>Brachytherapy, 2013-03, Vol.12 (2), p.171-177</ispartof><rights>American Brachytherapy Society</rights><rights>2013 American Brachytherapy Society</rights><rights>Copyright © 2013 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c463t-8b4762ce8c42575d2c6453155e46ff887cae1ab11c8fbe58463f6c2510bc3a803</citedby><cites>FETCH-LOGICAL-c463t-8b4762ce8c42575d2c6453155e46ff887cae1ab11c8fbe58463f6c2510bc3a803</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.brachy.2012.08.001$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22999975$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bult, Wouter</creatorcontrib><creatorcontrib>Vente, Maarten A.D</creatorcontrib><creatorcontrib>Vandermeulen, Eva</creatorcontrib><creatorcontrib>Gielen, Ingrid</creatorcontrib><creatorcontrib>Seevinck, Peter R</creatorcontrib><creatorcontrib>Saunders, Jimmy</creatorcontrib><creatorcontrib>van het Schip, Alfred D</creatorcontrib><creatorcontrib>Bakker, Chris J.G</creatorcontrib><creatorcontrib>Krijger, Gerard C</creatorcontrib><creatorcontrib>Peremans, Kathelijne</creatorcontrib><creatorcontrib>Nijsen, Johannes F.W</creatorcontrib><title>Microbrachytherapy using holmium-166 acetylacetonate microspheres: A pilot study in a spontaneous cancer animal model</title><title>Brachytherapy</title><addtitle>Brachytherapy</addtitle><description>Abstract Purpose Holmium-166 acetylacetonate microspheres (166 Ho-AcAc-MS) are proposed as an intratumoral radioablation device. This article presents a pilot study in housecats with unresectable liver cancer. Feasibility and tolerability of intratumoral administrations of166 Ho-AcAc-MS was investigated. Methods and Materials Three cats with unresectable liver tumors of different histotype were included. One cat had hepatocellular carcinoma (HCC), one had cholangiocarcinoma (CC), and one had a malignant epithelial liver tumor (MELT) of unspecified histotype.166 Ho-AcAc-MS were injected percutaneously under ultrasound guidance into the tumors. Followup consisted of physical examinations and hematologic and biochemical analyses. Results166 Ho-AcAc-MS were administered to three liver tumor-bearing cats. The treatment was well tolerated and the clinical condition, that is body weight, alertness, mobility, and coat condition of the animals improved markedly. Most biochemical and hematologic parameters normalized shortly after treatment. Life of all cats was extended and associated with a good quality of life. The HCC cat that received 33-Gy tumor-absorbed dose was euthanized 6 months after the first administration owing to disease progression. The MELT cat received 99-Gy tumor dose and was euthanized 3 months posttreatment owing to bacterial meningitis. The CC cat received 333 Gy and succumbed 4 months after the first treatment owing to the formation of a pulmonary embolism. Conclusions Percutaneous intratumoral injection of radioactive166 Ho-AcAc-MS is feasible in liver tumor-bearing cats. The findings of this pilot study indicate that166 Ho-AcAc-MS may constitute safe brachytherapeutic microspheres and warrant studies to confirm the clinical utility of this novel brachytherapy device.</description><subject>Animals</subject><subject>Brachytherapy</subject><subject>Brachytherapy - adverse effects</subject><subject>Brachytherapy - instrumentation</subject><subject>Brachytherapy - methods</subject><subject>Cats</subject><subject>Cell Line, Tumor</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Holmium - adverse effects</subject><subject>Holmium - chemistry</subject><subject>Holmium - therapeutic use</subject><subject>Holmium-166</subject><subject>Hydroxybutyrates - chemistry</subject><subject>Liver cancer</subject><subject>Liver Neoplasms - radiotherapy</subject><subject>Microsphere</subject><subject>Microspheres</subject><subject>Miniaturization</subject><subject>Pentanones - chemistry</subject><subject>Pilot Projects</subject><subject>Radioablation</subject><subject>Radioisotopes - adverse effects</subject><subject>Radioisotopes - chemistry</subject><subject>Radioisotopes - therapeutic use</subject><subject>Radiology</subject><subject>Treatment Outcome</subject><subject>β-emitter</subject><issn>1538-4721</issn><issn>1873-1449</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkbuO1jAQhSMEYi_wBgi5pEnwPQ4F0moFLNIiCqC2HGfC7x_HDnaClLfHURYKGlzYLs45M_NNVb0guCGYyNfnpk_GnraGYkIbrBqMyaPqkqiW1YTz7nH5C6Zq3lJyUV3lfC4C2TH2tLqgtCunFZfV-snZFI-k5QTJzBtaswvf0Sn6ya1TTaRExsKy-f2OwSyApt2U56KH_AbdoNn5uKC8rMOGXEAG5TmGxQSIa0bWBAsJmeAm49EUB_DPqiej8RmeP7zX1bf3777e3tX3nz98vL25ry2XbKlVz1tJLSjLqWjFQK3kghEhgMtxVKq1BojpCbFq7EGoYhqlpYLg3jKjMLuuXh25c4o_V8iLnly24P3RmiYlTDLe8a5I-SHdJ8sJRj2n0nDaNMF6B67P-sCkd-AaK114FtvLhwprP8Hw1_SHcBG8PQRQ5vzlIOlsHRQig0tgFz1E978K_wZY74Kzxv-ADfI5rikUhproXDz6y770feeEFndHOfsNUuCp6w</recordid><startdate>20130301</startdate><enddate>20130301</enddate><creator>Bult, Wouter</creator><creator>Vente, Maarten A.D</creator><creator>Vandermeulen, Eva</creator><creator>Gielen, Ingrid</creator><creator>Seevinck, Peter R</creator><creator>Saunders, Jimmy</creator><creator>van het Schip, Alfred D</creator><creator>Bakker, Chris J.G</creator><creator>Krijger, Gerard C</creator><creator>Peremans, Kathelijne</creator><creator>Nijsen, Johannes F.W</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20130301</creationdate><title>Microbrachytherapy using holmium-166 acetylacetonate microspheres: A pilot study in a spontaneous cancer animal model</title><author>Bult, Wouter ; Vente, Maarten A.D ; Vandermeulen, Eva ; Gielen, Ingrid ; Seevinck, Peter R ; Saunders, Jimmy ; van het Schip, Alfred D ; Bakker, Chris J.G ; Krijger, Gerard C ; Peremans, Kathelijne ; Nijsen, Johannes F.W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c463t-8b4762ce8c42575d2c6453155e46ff887cae1ab11c8fbe58463f6c2510bc3a803</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Animals</topic><topic>Brachytherapy</topic><topic>Brachytherapy - adverse effects</topic><topic>Brachytherapy - instrumentation</topic><topic>Brachytherapy - methods</topic><topic>Cats</topic><topic>Cell Line, Tumor</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Holmium - adverse effects</topic><topic>Holmium - chemistry</topic><topic>Holmium - therapeutic use</topic><topic>Holmium-166</topic><topic>Hydroxybutyrates - chemistry</topic><topic>Liver cancer</topic><topic>Liver Neoplasms - radiotherapy</topic><topic>Microsphere</topic><topic>Microspheres</topic><topic>Miniaturization</topic><topic>Pentanones - chemistry</topic><topic>Pilot Projects</topic><topic>Radioablation</topic><topic>Radioisotopes - adverse effects</topic><topic>Radioisotopes - chemistry</topic><topic>Radioisotopes - therapeutic use</topic><topic>Radiology</topic><topic>Treatment Outcome</topic><topic>β-emitter</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bult, Wouter</creatorcontrib><creatorcontrib>Vente, Maarten A.D</creatorcontrib><creatorcontrib>Vandermeulen, Eva</creatorcontrib><creatorcontrib>Gielen, Ingrid</creatorcontrib><creatorcontrib>Seevinck, Peter R</creatorcontrib><creatorcontrib>Saunders, Jimmy</creatorcontrib><creatorcontrib>van het Schip, Alfred D</creatorcontrib><creatorcontrib>Bakker, Chris J.G</creatorcontrib><creatorcontrib>Krijger, Gerard C</creatorcontrib><creatorcontrib>Peremans, Kathelijne</creatorcontrib><creatorcontrib>Nijsen, Johannes F.W</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Brachytherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bult, Wouter</au><au>Vente, Maarten A.D</au><au>Vandermeulen, Eva</au><au>Gielen, Ingrid</au><au>Seevinck, Peter R</au><au>Saunders, Jimmy</au><au>van het Schip, Alfred D</au><au>Bakker, Chris J.G</au><au>Krijger, Gerard C</au><au>Peremans, Kathelijne</au><au>Nijsen, Johannes F.W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Microbrachytherapy using holmium-166 acetylacetonate microspheres: A pilot study in a spontaneous cancer animal model</atitle><jtitle>Brachytherapy</jtitle><addtitle>Brachytherapy</addtitle><date>2013-03-01</date><risdate>2013</risdate><volume>12</volume><issue>2</issue><spage>171</spage><epage>177</epage><pages>171-177</pages><issn>1538-4721</issn><eissn>1873-1449</eissn><abstract>Abstract Purpose Holmium-166 acetylacetonate microspheres (166 Ho-AcAc-MS) are proposed as an intratumoral radioablation device. This article presents a pilot study in housecats with unresectable liver cancer. Feasibility and tolerability of intratumoral administrations of166 Ho-AcAc-MS was investigated. Methods and Materials Three cats with unresectable liver tumors of different histotype were included. One cat had hepatocellular carcinoma (HCC), one had cholangiocarcinoma (CC), and one had a malignant epithelial liver tumor (MELT) of unspecified histotype.166 Ho-AcAc-MS were injected percutaneously under ultrasound guidance into the tumors. Followup consisted of physical examinations and hematologic and biochemical analyses. Results166 Ho-AcAc-MS were administered to three liver tumor-bearing cats. The treatment was well tolerated and the clinical condition, that is body weight, alertness, mobility, and coat condition of the animals improved markedly. Most biochemical and hematologic parameters normalized shortly after treatment. Life of all cats was extended and associated with a good quality of life. The HCC cat that received 33-Gy tumor-absorbed dose was euthanized 6 months after the first administration owing to disease progression. The MELT cat received 99-Gy tumor dose and was euthanized 3 months posttreatment owing to bacterial meningitis. The CC cat received 333 Gy and succumbed 4 months after the first treatment owing to the formation of a pulmonary embolism. Conclusions Percutaneous intratumoral injection of radioactive166 Ho-AcAc-MS is feasible in liver tumor-bearing cats. The findings of this pilot study indicate that166 Ho-AcAc-MS may constitute safe brachytherapeutic microspheres and warrant studies to confirm the clinical utility of this novel brachytherapy device.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>22999975</pmid><doi>10.1016/j.brachy.2012.08.001</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1538-4721
ispartof Brachytherapy, 2013-03, Vol.12 (2), p.171-177
issn 1538-4721
1873-1449
language eng
recordid cdi_proquest_miscellaneous_1315634949
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Animals
Brachytherapy
Brachytherapy - adverse effects
Brachytherapy - instrumentation
Brachytherapy - methods
Cats
Cell Line, Tumor
Hematology, Oncology and Palliative Medicine
Holmium - adverse effects
Holmium - chemistry
Holmium - therapeutic use
Holmium-166
Hydroxybutyrates - chemistry
Liver cancer
Liver Neoplasms - radiotherapy
Microsphere
Microspheres
Miniaturization
Pentanones - chemistry
Pilot Projects
Radioablation
Radioisotopes - adverse effects
Radioisotopes - chemistry
Radioisotopes - therapeutic use
Radiology
Treatment Outcome
β-emitter
title Microbrachytherapy using holmium-166 acetylacetonate microspheres: A pilot study in a spontaneous cancer animal model
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T19%3A50%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Microbrachytherapy%20using%20holmium-166%20acetylacetonate%20microspheres:%20A%20pilot%20study%20in%20a%20spontaneous%20cancer%20animal%20model&rft.jtitle=Brachytherapy&rft.au=Bult,%20Wouter&rft.date=2013-03-01&rft.volume=12&rft.issue=2&rft.spage=171&rft.epage=177&rft.pages=171-177&rft.issn=1538-4721&rft.eissn=1873-1449&rft_id=info:doi/10.1016/j.brachy.2012.08.001&rft_dat=%3Cproquest_cross%3E1315634949%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1315634949&rft_id=info:pmid/22999975&rft_els_id=1_s2_0_S1538472112001924&rfr_iscdi=true